These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6118118)

  • 1. The clinical importance of lipid solubility in beta blockers.
    Neil-Dwyer G
    Aviat Space Environ Med; 1981 Nov; 52(11 Pt 2):S19-22. PubMed ID: 6118118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-blocker brain concentrations in man.
    Cruickshank JM; Neil-Dwyer G
    Eur J Clin Pharmacol; 1985; 28 Suppl():21-3. PubMed ID: 2865144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hallucinations and vivid dreams by use of metoprolol].
    Ahmed AI; van Mierlo PJ; van Waarde JA; Jansen PA
    Tijdschr Psychiatr; 2010; 52(2):117-21. PubMed ID: 20146183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-adrenoceptor blockers and the blood-brian barrier.
    Neil-Dwyer G; Bartlett J; McAinsh J; Cruickshank JM
    Br J Clin Pharmacol; 1981 Jun; 11(6):549-53. PubMed ID: 6115665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical use of beta blockers in hypertension.
    Sleight P
    Aviat Space Environ Med; 1981 Nov; 52(11 Pt 2):S3-8. PubMed ID: 6118120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers.
    Westerlund A
    Eur J Clin Pharmacol; 1985; 28 Suppl():73-6. PubMed ID: 2865153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Atenolol or metoprolol as beta-blocker in the treatment of hypertension].
    van den Born BJ; Brewster LM; Koopmans RP; van Montfrans GA
    Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1808-9. PubMed ID: 16121668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of 3-month treatment with propranolol, oxprenolol, metoprolol and pindolol on plasma lipids and lipoproteins in patients with primary arterial hypertension].
    Sznajderman M; Cybulska I; Niegowska J; Zawadzki Z; Sznajderman M
    Kardiol Pol; 1985; 28(7):489-99. PubMed ID: 2868145
    [No Abstract]   [Full Text] [Related]  

  • 10. Do we need a new classification of beta-blockers?
    Kendall MJ
    J Hum Hypertens; 1990 Jun; 4 Suppl 2():27-9. PubMed ID: 1973460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis.
    Zhang Y; Sun N; Jiang X; Xi Y
    J Am Soc Hypertens; 2017 Jul; 11(7):394-401. PubMed ID: 28760243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-blockers in the treatment of hypertension: are there clinically relevant differences?
    Weir MR
    Postgrad Med; 2009 May; 121(3):90-8. PubMed ID: 19491545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose kinetics of oral propranolol, metoprolol, atenolol, and sotalol: relation to lipophilicity.
    Ochs HR; Greenblatt DJ; Arendt RM; Schäfer-Korting M; Mutschler E
    Arzneimittelforschung; 1985; 35(10):1580-2. PubMed ID: 2866772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility.
    Conant J; Engler R; Janowsky D; Maisel A; Gilpin E; LeWinter M
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):656-61. PubMed ID: 2471005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blockers, dyslipidemia, and coronary artery disease. A reassessment.
    Burris JF
    Arch Intern Med; 1993 Sep; 153(18):2085-92. PubMed ID: 8104394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Which beta receptor blockers should be used in hypertension?].
    Werning C
    Fortschr Med; 1980 Feb; 98(5):157-60. PubMed ID: 6102958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockers and hypertension: carbon copies or a real choice.
    Whipps RG; Fisher ML; Plotnick GD
    Compr Ther; 1984 Sep; 10(9):12-8. PubMed ID: 6149036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant beta-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension.
    Beitelshees AL; Zineh I; Yarandi HN; Pauly DF; Johnson JA
    Pharmacotherapy; 2006 Sep; 26(9):1247-54. PubMed ID: 16945046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.